FDA per­ma­nent­ly lifts in-per­son re­quire­ments for dis­pens­ing abor­tion pills

Since the pan­dem­ic be­gan, the FDA has al­lowed women to ac­cess the abor­tion drug mifepri­s­tone via the mail, mak­ing it eas­i­er for them and en­sur­ing that they don’t have to go to a clin­ic to re­ceive the pills.

The FDA’s tem­po­rary change be­came per­ma­nent on Thurs­day af­ter­noon, with the FDA an­nounc­ing that the REMS on mifepri­s­tone (brand name Mifeprex) and its gener­ic ver­sions must be mod­i­fied by re­mov­ing this in-per­son dis­pens­ing re­quire­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER